Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Several other research firms have also commented on AGIO. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 1st. Cann reissued a “buy” rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 18th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $61.00 price target on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $62.88.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) traded up 3.07% during midday trading on Thursday, hitting $59.18. 833,983 shares of the stock traded hands. The firm’s market cap is $2.85 billion. Agios Pharmaceuticals has a 12-month low of $35.84 and a 12-month high of $67.74. The company’s 50-day moving average is $49.86 and its 200 day moving average is $48.86.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The business had revenue of $10.51 million during the quarter, compared to analyst estimates of $9.65 million. During the same quarter last year, the firm posted ($0.64) earnings per share. The business’s revenue for the quarter was down 66.4% compared to the same quarter last year. On average, analysts anticipate that Agios Pharmaceuticals will post ($6.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Upgraded to Hold by ValuEngine” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/06/24/agios-pharmaceuticals-inc-agio-upgraded-to-hold-by-valuengine.html.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Biller sold 4,292 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $55.00, for a total transaction of $236,060.00. The disclosure for this sale can be found here. Insiders sold a total of 26,600 shares of company stock worth $1,423,540 over the last ninety days. Corporate insiders own 10.55% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $105,000. Bank of Montreal Can raised its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $129,000. Russell Investments Group Ltd. raised its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares during the last quarter. Finally, Advantage Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares during the last quarter. 83.99% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.